Pfizer Inc. $PFE Holdings Reduced by Huntington National Bank

Posted by Brian Himes on May 29th, 2026

Huntington National Bank decreased its position in Pfizer Inc. (NYSE:PFE – Free Report) by 4.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 514,976 shares of the biopharmaceutical company’s stock after selling 22,317 shares during the period. Huntington National Bank’s holdings in Pfizer were worth $12,823,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares during the last quarter. State Street Corp grew its position in Pfizer by 0.9% in the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after purchasing an additional 2,786,098 shares during the last quarter. Geode Capital Management LLC grew its position in Pfizer by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock worth $3,235,642,000 after purchasing an additional 1,184,728 shares during the last quarter. Northern Trust Corp grew its position in Pfizer by 1.4% in the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock worth $1,631,225,000 after purchasing an additional 869,175 shares during the last quarter. Finally, Fisher Asset Management LLC grew its position in Pfizer by 5.4% in the 4th quarter. Fisher Asset Management LLC now owns 51,952,106 shares of the biopharmaceutical company’s stock worth $1,293,607,000 after purchasing an additional 2,664,052 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on PFE shares. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Morgan Stanley upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. HSBC upped their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. CICC Research initiated coverage on shares of Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target for the company. Finally, Wolfe Research reaffirmed an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus price target of $28.82.

Read Our Latest Stock Report on PFE

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer and Innovent Biologics announced a global licensing and collaboration deal to research and develop 12 early-stage cancer medicines, with potential value of up to $10.5 billion. The agreement expands Pfizer’s oncology pipeline and could create long-term revenue opportunities. Reuters article
Positive Sentiment: The companies also described the partnership as a strategic global collaboration covering ADCs and multi-specific antibodies, which suggests Pfizer is strengthening its next-generation cancer portfolio. PR Newswire article
Positive Sentiment: Recent coverage also highlighted steady early-stage pipeline progress, including a new Phase 1 trial update, reinforcing the view that Pfizer has several development programs moving forward. TipRanks article
Neutral Sentiment: Bank of America recently lifted its price target on Pfizer to $27 from $26 after stronger quarterly results, indicating slightly improved sentiment but still a cautious overall stance. Yahoo Finance article

Pfizer Trading Down 0.2%

Shares of NYSE:PFE opened at $26.16 on Friday. The company has a 50 day moving average of $26.79 and a 200-day moving average of $26.28. The firm has a market cap of $149.07 billion, a P/E ratio of 19.97 and a beta of 0.35. Pfizer Inc. has a twelve month low of $23.06 and a twelve month high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.6%. Pfizer’s dividend payout ratio is currently 131.30%.

Pfizer Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.